Literature DB >> 6142350

Evidence that thyroid-stimulating antibody is produced in the thyroid gland.

P Kendall-Taylor, A J Knox, N R Steel, S Atkinson.   

Abstract

The hyperthyroidism in Graves' disease results from the action of thyroid-stimulating antibodies (TSAb). The thyroid gland in Graves' disease shows diffuse lymphocytic infiltration, and after removal of the gland antibody titres usually decline and patients go into remission. It is postulated that the lymphocytes in the thyroid may be an important site of TSAb production. 10 patients with Graves' disease and 8 patients with other thyroid disorders were studied. Blood was taken during operation, but before thyroid mobilisation, from the thyroid vein and simultaneously from a peripheral vein. In patients with Graves' disease the concentration of TSAb activity in the thyroid vein was much greater than that in the peripheral vein. TSAb was not detected in either peripheral vein or thyroid vein samples in the other patients. The increase in TSAb concentration in the thyroid vein indicates production of antibodies by lymphocytes within the thyroid and could explain why removal of the thyroid results in disappearance of TSAb from the circulation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6142350     DOI: 10.1016/s0140-6736(84)92171-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

1.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

2.  Graves' disease: changes in TSH receptor and anti-microsomal antibodies after thyroidectomy.

Authors:  T W De Bruin; N A Patwardhan; R S Brown; L E Braverman
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

3.  Absence of gradient of thyrotropin receptor antibody and T cell subset distribution between thyroid and peripheral venous blood in patients with Graves' disease prepared for surgery with carbimazole and potassium iodide.

Authors:  R Wilson; J H McKillop; C Pearson; A K Burnett; I Gunn; A M McNicol; J A Thomson
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

4.  Thyroid stimulating immunoglobulin (TSI) synthesis by pokeweed mitogen (PWM) stimulated peripheral blood lymphocytes (PBL) from Graves' disease (GD) patients.

Authors:  B Pautard; J J Rémy; J Charreire
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

5.  The presence of higher levels of thyroglobulin, but not thyroid autoantibodies, in the thyroid vein in Graves' disease.

Authors:  F F Chou; P W Wang; S M Sheen-Chen
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

6.  Retrospective analysis of prognostic factors affecting the thyroid functional status after subtotal thyroidectomy for Graves' disease.

Authors:  T Okamoto; Y Fujimoto; T Obara; Y Ito; M Aiba
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.